REGENXBIO Inc. (RGNX) Operating Margin
- Operating margin · 12 months: Value -94.08%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -94.08% | Operating income / revenue. Period ending 2026-06-30. $-164.15M ÷ $174.48M × 100 ≈ -94.08% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -164.15M USD | Operating Income (Loss) |
| Revenue | 174.48M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | Cost of Goods and Services Sold |
| Research and development | 229.14M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-164.15M | $174.48M | (m) | $229.14M | (m) | -94.08% |
| 2026-03-31 | $-256.69M | $87.82M | (m) | $232.55M | (m) | -292.28% |
| 2025-12-31 | $-161.20M | $170.44M | (m) | $228.30M | (m) | -94.58% |
| 2025-09-30 | $-154.93M | $161.32M | (m) | $219.07M | (m) | -96.04% |
| 2025-06-30 | $-164.60M | $155.78M | (m) | $217.40M | (m) | -105.66% |
| 2025-03-31 | $-157.36M | $156.72M | (m) | $206.76M | (m) | -100.41% |
| 2024-12-31 | $-233.35M | $83.33M | $33.57M | $208.52M | (m) | -280.03% |
| 2024-09-30 | $-245.88M | $84.33M | $38.49M | $213.82M | (m) | -291.58% |
| 2024-06-30 | $-248.76M | $89.04M | $38.49M | $217.58M | (m) | -279.37% |
| 2024-03-31 | $-265.83M | $86.73M | $37.38M | $228.59M | (m) | -306.52% |
| 2023-12-31 | $-268.13M | $90.24M | $37.21M | $232.27M | (m) | -297.12% |
| 2023-09-30 | $-262.00M | $99.37M | $38.76M | $239.09M | (m) | -263.65% |
| 2023-06-30 | $-268.08M | $96.97M | $39.46M | $244.22M | (m) | -276.45% |
| 2023-03-31 | $-257.51M | $109.64M | $42.94M | $245.34M | (m) | -234.86% |
| 2022-12-31 | $-262.88M | $112.72M | $54.55M | $242.45M | (m) | -233.20% |
| 2022-09-30 | $108.49M | $480.03M | $64.82M | $227.93M | (m) | 22.60% |
| 2022-06-30 | $122.19M | $484.30M | $65.83M | $212.47M | (m) | 25.23% |
| 2022-03-31 | $132.50M | $473.68M | $62.70M | $197.34M | (m) | 27.97% |
| 2021-12-31 | $159.98M | $470.35M | $51.83M | $181.44M | (m) | 34.01% |
| 2021-09-30 | $-207.27M | $93.14M | $39.03M | $180.64M | (m) | -222.54% |
| 2021-06-30 | $-135.97M | $161.28M | $42.29M | $176.75M | (m) | -84.31% |
| 2021-03-31 | $-125.58M | $155.81M | $37.16M | $168.98M | (m) | -80.60% |
| 2020-12-31 | $-119.23M | $154.57M | $35.71M | $166.29M | (m) | -77.14% |
| 2020-09-30 | $-105.91M | $144.89M | $29.25M | $152.92M | (m) | -73.09% |
| 2020-06-30 | $-155.75M | $60.68M | $14.38M | $144.65M | (m) | -256.69% |
| 2020-03-31 | $-150.79M | $51.99M | $11.62M | $136.02M | (m) | -290.02% |
| 2019-12-31 | $-149.00M | $35.23M | $8.24M | $124.19M | (m) | -422.89% |
| 2019-09-30 | $-106.22M | $64.24M | (m) | $114.71M | (m) | -165.35% |
| 2019-06-30 | $-93.05M | $54.85M | (m) | $97.52M | (m) | -169.66% |
| 2019-03-31 | $-49.83M | $87.00M | (m) | $89.53M | (m) | -57.28% |
| 2018-12-31 | $88.10M | $218.50M | (m) | $83.87M | (m) | 40.32% |
| 2018-09-30 | $69.05M | $179.77M | (m) | $73.71M | (m) | 38.41% |
| 2018-06-30 | $70.47M | $175.80M | (m) | $67.72M | (m) | 40.08% |
| 2018-03-31 | $49.06M | $142.33M | (m) | $60.16M | (m) | 34.47% |
| 2017-12-31 | $-75.89M | $10.39M | (m) | $57.22M | (m) | -730.15% |
| 2017-09-30 | $-79.76M | $10.05M | (m) | $59.11M | (m) | -793.67% |
| 2017-06-30 | $-77.11M | $8.84M | (m) | $59.16M | (m) | -872.54% |
| 2017-03-31 | $-77.01M | $4.65M | (m) | $55.92M | (m) | -1655.79% |
| 2016-12-31 | $-65.34M | $4.59M | (m) | $45.48M | (m) | -1423.84% |
| 2016-09-30 | $-50.37M | $7.34M | (m) | $34.23M | (m) | -686.15% |
| 2016-06-30 | $-39.05M | $8.35M | (m) | $27.34M | (m) | -467.73% |
| 2016-03-31 | $-30.39M | $7.34M | (m) | $20.67M | (m) | -414.27% |
| 2015-12-31 | $-23.14M | $7.59M | (m) | $17.28M | (m) | -304.92% |
| 2015-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | $3.64M | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | $3.83M | (m) | (m) | (m) | (m) |
| 2014-12-31 | $-3.68M | $6.12M | (m) | $4.96M | (m) | -60.16% |
| 2014-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | $-4.78M | $6.09M | (m) | $5.05M | (m) | -78.46% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |